Exscientia receives first cta approval to initiate ignite-ai, a phase 1/2 trial of exs-21546 in patients with advanced solid tumours

Oxford, england--( business wire )--exscientia plc (nasdaq: exai) today announced clinical trial application (cta) approval of ignite-ai, enabling site activation in its first european country. ignite-ai is a phase 1/2 trial studying exs-21546 ('546), exscientia's a2a receptor antagonist in combination with anti-pd-1 therapy in patients with immunotherapy relapsed or refractory renal cell carcinoma (rcc) and non-small cell lung cancer (nsclc). the study will evaluate safety, efficacy, pharmacokinetics and pharmacodynamics in up to 110 patients. exscientia intends to expand to additional tumour types, including breast cancer, in future trials after assessment of ‘546 activity and validation of its selection biomarkers.
EXAI Ratings Summary
EXAI Quant Ranking